CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Nasdaq Biological Products, (No Diagnostic Substances) NV CIK: 0001187953
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Creative Medical Technology Holdings has deteriorated to zero revenue with -45.5% YoY decline, indicating complete operational collapse or stalled business model. The company is burning $1.3M in cash per period against only $5.7M in reserves, providing minimal 4-5 quarter runway. Without immediate revenue generation or path to profitability, severe financial distress is imminent.

Strengths

  • + Strong liquidity position with 19.69x current ratio provides immediate debt servicing capability
  • + Cash reserves of $5.7M provide short-term financial cushion and operational flexibility
  • + Manageable debt-to-equity ratio of 0.84x limits financial leverage and bankruptcy risk

Risks

  • ! Zero revenue with 45.5% YoY decline indicates complete loss of business operations or early-stage pre-revenue failure
  • ! Negative operating cash flow of -$1.3M rapidly depletes remaining cash reserves within 4-5 quarters
  • ! Persistent operating losses (-$1.5M) and net losses (-$1.4M) with no visible path to profitability

Key Metrics to Watch

Financial Metrics

Revenue
0.0
Net Income
-1.4M
EPS (Diluted)
$-0.38
Free Cash Flow
-1.3M
Total Assets
6.4M
Cash
5.7M

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -23.0%
ROA -21.8%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
19.69x
Quick Ratio
19.29x
Debt/Equity
0.84x
Debt/Assets
4.8%
Interest Coverage
N/A
Long-term Debt
5.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-10T07:20:25.913433 | Data as of: 2026-03-31 | Powered by Claude AI